UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934
Date of Report (Date of earliest event reported): August 31, 2006

BRISTOL-MYERS SQUIBB COMPANY
(Exact Name of Registrant as Specified in its Charter)

 
					
Delaware	 	1-1136	 	22-079-0350	
(State or Other Jurisdiction
of Incorporation)	 	(Commission File Number)	 	(IRS Employer
Identification Number)	
345 Park Avenue
New York, NY, 10154
(Address of Principal Executive Office)
Registrant’s telephone number, including area code: (212) 546-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
 
¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	
 
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
 
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
 
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	

Item 2.02. Results of Operations and Financial Condition.
On August 31, 2006, Bristol-Myers Squibb Company (the “Company”) posted additional supplemental information on the Company’s website at www.bms.com. This additional supplemental information includes net sales, months on hand, and estimated demand information for key products and growth drivers as of June 30, 2006 for the Company’s International Pharmaceutical, Nutritionals and Other Health Care reporting segments. Net sales and months on hand information is also provided as of March 31, 2006, June 30, 2005 and March 31, 2005. The additional supplemental information is furnished and  incorporated by reference as Exhibit 99.1 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
    99.1.    Additional supplemental information posted on Bristol-Myers Squibb Company’s website at www.bms.com

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	 	BRISTOL-MYERS SQUIBB COMPANY	
			
Dated: August 31, 2006	 	By:	 	/s/ Sandra Leung	
	 	Name:	 	Sandra Leung	
	 	Title:	 	Secretary	

EXHIBIT INDEX

Exhibit No.	 	Description	
99.1	 	Additional supplemental information posted on Bristol-Myers Squibb Company’s website at www.bms.com	
 
Exhibit 99.1
International Pharmaceuticals, Nutritionals and Other Health Care
Estimated End-User Demand
The following table sets forth for each of the Company’s key pharmaceutical products and growth drivers sold by the Company’s International Pharmaceuticals reporting segment, including the top 15 pharmaceutical products sold in the Company’s major non-U.S. countries (based on 2005 net sales), and for each of the key products sold by the other reporting segments listed below, the percentage change in the Company’s estimated ultimate patient/consumer demand for the month of June 2006 compared to the month of June 2005. The Company commenced collecting the estimated ultimate patient/consumer demand for these reporting segments with the March 2005 period. The Company believes the year-to-year comparison below provides a more meaningful comparison to changes in sales for the quarter than the quarter-to-prior quarter comparisons previously provided.

   	  	% Change in Demand on a
Constant U.S. Dollar Basis	
   	  	June 2006
vs. June 2005	
International Pharmaceuticals	  		
ABILIFY* (total revenue)	  	21	
AVAPRO*/AVALIDE*	  	(1)	
BARACLUDE	  	NA	
BUFFERIN*	  	30	
CAPOTEN	  	(32)	
DAFALGAN	  	(10)	
EFFERALGAN	  	(10)	
MAXIPIME	  	(15)	
MONOPRIL	  	(23)	
PARAPLATIN	  	(14)	
PERFALGAN	  	6	
PLAVIX*	  	(4)	
PRAVACHOL	  	(39)	
REYATAZ	  	38	
SUSTIVA	  	13	
TAXOL ®  (paclitaxel)	  	(21)	
VIDEX/VIDEX EC	  	(36)	
Nutritionals	  		
ENFAMIL/ENFAGROW	  	4	
NUTRAMIGEN	  	15	
Other Health Care	  		
ConvaTec	  		
Ostomy	  	7	
Wound Therapeutics	  	2	
Medical Imaging	  		
CARDIOLITE	  	(6)	
Estimated Inventory Months on Hand in the Distribution Channel
As previously disclosed, for the Company’s Pharmaceuticals business outside of the United States, Nutritionals and Other Health Care business units around the world, the Company has significantly more direct customers, limited information on direct customer product level inventory and corresponding out-movement information and the reliability of third party demand information, where available, varies widely. Accordingly, the Company relies on a variety of methods to estimate direct customer product level inventory and to calculate months on hand for these business units.

The following table sets forth for each of the Company’s key products sold by the reporting segments listed below, the net sales of the applicable product for each of the quarters ended June 30, 2006, March 31, 2006, June 30, 2005, and March 31, 2005, and the estimated number of months on hand of the applicable product in the direct customer distribution channel for the reporting segment as of the end of each of the four quarters. The estimates of months on hand for key products described below for the International Pharmaceuticals reporting segment are based on data collected for all of the Company’s significant business units outside of the United States. Also described further below is information on non-key product(s) where the amount of inventory on hand at direct customers is more than approximately one month and the impact is not de minimis. For the other reporting segments, estimates are based on data collected for the United States and all significant business units outside of the United States.

 	  	June 30, 2006	  	March 31, 2006	 	 	June 30, 2005	  	March 31, 2005	
 	  	Net Sales
(Dollars
in Millions)	  	Months
on Hand	  	Net Sales
(Dollars
in Millions)	  	Months
on Hand	 	 	Net Sales
(Dollars
in Millions	  	Months
on Hand	  	Net Sales
(Dollars
in Millions	  	Months
on Hand	
International Pharmaceuticals	  			  		  			  			 			  		  			  		
ABILIFY* (total revenue)	  	$	57	  	0.6	  	$	52	  	0.6	 	 	$	40	  	0.6	  	$	27	  	0.6	
AVAPRO*/AVALIDE*	  	 	113	  	0.5	  	 	94	  	0.5	 	 	 	101	  	0.4	  	 	94	  	0.4	
BARACLUDE	  	 	5	  	1.0	  	 	2	  	1.1	 	 	 	—  	  	—  	  	 	—  	  	—  	
BUFFERIN*	  	 	31	  	0.5	  	 	22	  	0.6	 	 	 	32	  	1.0	  	 	26	  	0.5	
CAPOTEN	  	 	31	  	0.9	  	 	35	  	0.8	 	 	 	42	  	0.8	  	 	42	  	0.8	
DAFALGAN	  	 	37	  	1.1	  	 	37	  	1.4	 	 	 	33	  	0.8	  	 	40	  	1.3	
EFFERALGAN	  	 	62	  	0.9	  	 	68	  	1.2	 	 	 	55	  	0.5	  	 	88	  	0.9	
MAXIPIME	  	 	43	  	0.8	  	 	40	  	0.8	 	 	 	52	  	0.8	  	 	46	  	0.7	
MONOPRIL	  	 	48	  	1.1	  	 	46	  	1.1	 	 	 	52	  	0.7	  	 	56	  	0.6	
PARAPLATIN	  	 	29	  	0.6	  	 	26	  	0.6	 	 	 	34	  	0.6	  	 	29	  	0.6	
PERFALGAN	  	 	51	  	0.6	  	 	46	  	0.6	 	 	 	42	  	0.6	  	 	42	  	0.5	
PLAVIX*	  	 	157	  	0.5	  	 	136	  	0.5	 	 	 	145	  	0.5	  	 	141	  	0.7	
PRAVACHOL	  	 	195	  	1.4	  	 	234	  	1.5	 	 	 	272	  	0.7	  	 	262	  	0.7	
REYATAZ	  	 	114	  	0.7	  	 	88	  	0.6	 	 	 	85	  	0.8	  	 	57	  	0.6	
SUSTIVA	  	 	78	  	0.5	  	 	67	  	0.5	 	 	 	70	  	0.6	  	 	70	  	0.5	
TAXOL ®  (paclitaxel)	  	 	145	  	0.5	  	 	143	  	0.6	 	 	 	182	  	0.5	  	 	201	  	0.5	
VIDEX/VIDEX EC	  	 	35	  	1.2	  	 	31	  	0.8	 	 	 	38	  	0.9	  	 	39	  	0.8	
Nutritionals	  			  		  			  			 			  		  			  		
ENFAMIL/ENFAGROW	  	 	312	  	0.9	  	 	304	  	0.9	 	 	 	299	  	0.9	  	 	285	  	0.9	
NUTRAMIGEN	  	 	54	  	1.0	  	 	48	  	1.0	 	 	 	47	  	1.0	  	 	44	  	1.0	
Other Health Care	  			  		  			  			 			  		  			  		
ConvaTec	  			  		  			  			 			  		  			  		
Ostomy	  	 	141	  	1.0	  	 	123	  	0.9	 	 	 	139	  	0.9	  	 	127	  	0.9	
Wound Therapeutics	  	 	107	  	0.9	  	 	98	  	0.9	1	 	 	103	  	0.8	  	 	97	  	0.8	
Medical Imaging	  			  		  			  			 			  		  			  		
CARDIOLITE	  	 	105	  	0.8	  	 	103	  	0.8	2	 	 	108	  	0.7	  	 	102	  	0.7	

1	The Company reported ConvaTec Wound Therapeutics Months on Hand of 0.8 as of March 31, 2006, in a Form 10-Q filed with the U.S. Securities Exchange Commission (“SEC”) on August 8, 2006 (“Second Quarter 10-Q”) and a Form 8-K/A filed with the SEC on May 31, 2006 (“May 31, 2006 Form 8-K/A”). The Company has since identified a technical error in the calculation of the ConvaTec Wound Therapeutics Months on Hand as of March 31, 2006. The corrected calculation is 0.9 and is reported in the table above.	
2	The Company reported CARDIOLITE Months on Hand of 0.7 as of March 31, 2006 in the Second Quarter 10-Q and the May 31, 2006 Form 8-K/A. The Company has since identified a technical error in the calculation of Months on Hand for CARDIOLITE as of March 31, 2006. The corrected calculation is 0.8 and is reported in the table above.	

The above months on hand information represents the Company’s estimates of aggregate product level inventory on hand at direct customers divided by the expected demand for the applicable product. Expected demand is the estimated ultimate patient/consumer demand calculated based on estimated end-user consumption or direct customer out-movement data over the most recent 31 day period or other reasonable period. Factors that may affect the Company’s estimates include generic competition, seasonality of products, direct customer purchases in light of price increases, new product or product presentation launches, new warehouse openings by direct customers, new customer stockings by direct customers and expected direct customer purchases for governmental bidding situations.
The Company relies on a variety of methods to calculate months on hand for these reporting segments. Where available, the Company relies on information provided by third parties to determine estimates of aggregate product level inventory on hand at direct customers and expected demand. For the reporting segments listed above, however, the Company has limited information on direct customer product level inventory, end-user consumption and direct customer out-movement data. Further, the quality of third party information, where available, varies widely. In some circumstances, such as the case with new products or seasonal products, such historical end-user consumption or out-movement information may not be available or applicable. In such cases, the Company uses estimated prospective demand. In cases where direct customer product level inventory, ultimate patient/consumer demand or out-movement data do not exist or are otherwise not available, the Company has developed a variety of other methodologies to calculate estimates of such data, including using such factors as historical sales made to direct customers and third party market research data related to prescription trends and end-user demand.
As of March 31, 2006, BARACLUDE, an antiviral product, had approximately 1.1 months of inventory on hand at direct customers. The level of inventory on hand is due primarily to stocking of the product in support of the launch in China.
As of June 30, 2006, March 31, 2006, and March 31, 2005, DAFALGAN, an analgesic product sold principally in Europe, had approximately 1.1months, 1.4 months, and 1.3 months of inventory on hand, respectively, at direct customers. The level of inventory on hand is due primarily to private pharmacists purchasing DAFALGAN approximately once every eight weeks and the seasonality of the product.
As of March 31, 2006, EFFERALGAN, an analgesic product sold principally in Europe, had approximately 1.2 months of inventory on hand at direct customers. The level of inventory on hand is due primarily to private pharmacists purchasing EFFERALGAN approximately once every eight weeks and the seasonality of the product.
As of June 30, 2006 and March 31, 2006, MONOPRIL, a cardiovascular product, had approximately 1.1 months and 1.1 months of inventory on hand, respectively, at direct customers. The level of inventory on hand is due primarily to supply of the product in support of its inclusion in a government program in Russia.
As of June 30, 2006 and March 31, 2006, PRAVACHOL, a cardiovascular product, had approximately 1.4 months and 1.5 months of inventory on hand, respectively, at direct customers. The increased level of inventory on hand is due primarily to an increase in orders from a significant direct customer in France. It is anticipated that the inventory levels for this customer will be worked down during the third and fourth quarters.
As of June 30, 2006, VIDEX/VIDEX EC, an antiviral product, had approximately 1.2 months of inventory on hand at direct customers. The increased level of inventory on hand is due primarily to government purchasing patterns in Brazil.
The Company continuously seeks to improve the quality of its estimates of months on hand of inventories held by its direct customers including thorough review of its methodologies and processes for

calculation of these estimates and review and analysis of its own and third parties’ data used in such calculations. The Company expects that it will continue to review and refine its methodologies and processes for calculation of these estimates and will continue to review and analyze its own and third parties’ data in such calculations. The Company also has and will continue to take steps to expedite the receipt and processing of data for the non-U.S. Pharmaceuticals business.

*	Indicates brand names of products which are registered trademarks not owned by the Company or its subsidiaries. ERBITUX is a trademark of ImClone Systems Inc.; AVAPRO, AVALIDE, and PLAVIX are trademarks of Sanofi-Aventis Corp.; and ABILIFY is a trademark of Otsuka Pharmaceuticals, Ltd. BUFFERIN is a trademark of Novartis AG in the United States, Canada, Europe and Latin America. BUFFERIN is a trademark of the Company in all other markets where it is registered.